1. Pfizer’s Vizimpro (Dacomitinib) Receives the US FDA Approval for 1L Treatment of mNSCLC with Epidermal Growth Factor Receptor (EGFR)

Published: 27 Sep, 2018 |Tags: Pfizer, Vizimpro, Receives, the US FDA Approval, 1L, Treatment, mNSCLC,    Epidermal Growth Factor Receptor (EGFR)

 

2.   Salix Signs an Exclusive Co-Promotion Agreement for Dova’s Doptelet in the US

Published: 27 Sep, 2018 |Tags: Salix Pharmaceuticals, Signs, Exclusive, Co-Promotion, Agreement, Dova Pharmaceuticals, Doptelet, the US, P-III ADAPT-1 , ADAPT-2    

3. Janssen Terminates Development and Commercialization Agreement with Geron for Imetelstat

Published: 27 Sep, 2018 |Tags: Janssen, Terminates, Development & Commercialization, Agreement, Geron, Imetelstat, J&J, IMbark P-II, IMerge P-II      

4. Novartis Signs a License and Collaboration Agreement with Cellular Biomedicine Group (CBMG) for CAR-T Cell Therapy in China

Published: 27 Sep, 2018 |Tags: Novartis, Signs, License, Collaboration, Agreement,Cellular Biomedicine Group (CBMG),  CAR-T Cell Therapy, China, M&A    

5. Lilly Receives FDA Approval for Emgality (galcanezumab-gnlm) for Preventive Treatment of Migraine in Adults

Published: 27 Sep, 2018 |Tags: Lilly, FDA, Approval, Emgality, (galcanezumab-gnlm), Preventive, Treatment, Migraine, Adults, P-III, EVOLVE-1 & EVOLVE-2, REGAIN    

6. Samsung Bioepis’ BLA for SB5 Adalimumab Biosimilar accepted for review by the USFDA

Published: 27 Sep, 2018 |Tags: Samsung Bioepis, BLA, SB5, Adalimumab Biosimilar, Accepted, the US FDA, EU, SB5, injectable, TNF, Australia TGA and Health Canada    

7. Lyra Therapeutics (formally 480 Biomedicals) developing Innovative Therapeutics for ENT Diseases Raises $29.5mn in Series B

Published: 26 Sep, 2018 |Tags: Lyra Therapeutics, developing, Innovative Therapeutics, ENT Diseases, Raises, $29.5M, Series B  

8. I-Mab Biopharma Expands Collaboration with Wuxi Biologics for Three More Antibody Programs

Published: 27 Sep, 2018 |Tags: I-Mab Biopharma, Expansion, Collaboration, Wuxi Biologics, Three More, Antibody Programs    

9. Alexion to Acquire Syntimmune for Antibody Therapeutics Targeting the Neonatal Fc Receptor (FcRn)

Published: 26 Sep, 2018 |Tags: Alexion, Acquires, Syntimmune, Antibody Therapeutics, Targeting Neonatal Fc Receptor (FcRn)    

10. Anaeropharma Science and Astellas Pharma Collaborates to Develop Novel Anti-Tumor Drugs Using i-DPS Technology

Published: 25 Sep, 2018 |Tags: Anaeropharma Science, Astellas Pharma, Collaborates, Develop, Novel, Anti-Tumor Drugs, i-DPS Technology, B. longum    

11. Agilent Technologies Acquires ACEA Biosciences to Strengthen Platform and Capabilities in Cell Analysis

Published: 25 Sep, 2018 | Tags: Agilent Technologies, Acquisition, ACEA Biosciences, Strengthen, Platform, Capabilities, Cell Analysis  

12. CSPC Pharmaceutical Signs Exclusive License Agreement with Verastem Oncology to Develop and Commercialize Copiktra in China

Published: 25 Sep, 2018 |Tags: CSPC Pharmaceutical, Exclusive, License Agreement, Verastem Oncology, Develop, Commercialize, Copiktra, China    

13. Coherus Biosciences’ Udenyca (Pegfilgrastim Biosimilar) Receives EU Marketing Approval for Febrile Neutropenia

Published: 25 Sep, 2018 |Tags: Coherus Biosciences, Udenyca, Pegfilgrastim Biosimilar, EU, Marketing Approval, Febrile Neutropenia  

14. Tris Pharma Acquires Pfizer’s NextWave Pharmaceuticals for its Two ADHD Treatments

Published: 25 Sep, 2018 |Tags: Tris Pharma, Acquires, Pfizer, NextWave Pharmaceuticals, Two ADHD Treatments, Quillivant XR, QuilliChew ER    

15. Stemcell Technologies and Brigham and Women’s Hospital Signs Exclusive License Agreement for Kidney Organoid Technology

Published: 25 Sep, 2018 |Tags: Stemcell Technologies, Brigham and Women’s Hospital, Exclusive, License Agreement, Kidney Organoid Technology, M&A  

16. Immuntep, Collaborated with Merck KGaA and Pfizer for Clinical Trial and Supply Agreement for Eftilagimod Alpha with Avelumab

Published: 24 Sep, 2018 |Tags: Immuntep, Collaborated, Merck KGaA and Pfizer, Avelumab, Clinical Trial and Supply Agreement, Eftilagimod Alpha, P-I trial  

17.  Amgen and Astellas’ Blincyto (blinatumomab, BiTE) Receives Japanese Marketing Approval for Treatment of R/R B-cell Acute Lymphoblastic Leukemia(ALL)

Published: 24 Sep, 2018 |Tags: Amgen, and Astellas, Blincyto, (blinatumomab, BiTE), Japanese Marketing Approval, Treatment, R/R B-cell Acute Lymphoblastic Leukemia(ALL), Ministry of Health Labour and Welfare, Japan,  

18. Mylan Collaborated with Atomo Diagnostics for Commercialization of HIV Rapid Diagnostic tests for Low and Middle-Income Countries

Published: 24 Sep, 2018 |Tags: Mylan, Collaborated, Atomo Diagnostics, Commercialization, CE-Marked, in-vitro HIV rapid Diagnostic tests, Low and Middle-Income Countries  

19.  Gilead’s subsidiary Asegua Therapeutics Plans to Launch Authorized Generic Versions in the US of Epclusa & Harvoni for the Treatment of Chronic Hepatitis C

Published: 24 Sep, 2018 |Tags: Gilead subsidiary, Asegua Therapeutics, Plans, Launch, Authorized, Generic Versions, the US, Epclusa & Harvoni, Treatment, Chronic Hepatitis C  

20. Enesi Pharma Signs a Cooperative R&D Agreement (CRADA) with the Walter Reed Army Institute of Research (WRAIR) for Shigella’s Vaccine Development

Published: 24 Sep, 2018 |Tags: Enesi Pharma, Cooperative R&D Agreement, Walter Reed Army Institute of Research, Shigella vaccine, development  

21. Sun Pharma’s Ilumya Receives Australian Therapeutic Goods Administration (TGA) Approval for the Treatment of Moderate-to-Severe Plaque Psoriasis

Published: 21 Sep, 2018 |Tags: Sun Pharma, Ilumya, Australian Therapeutic Goods Administration (TGA), Approval, Treatment, Moderate-to-Severe Plaque Psoriasis  

22. Bayer’s BAY94-9027 Receives CHMP Approval for the Treatment of Haemophilia A aged =12yrs.

Published: 21 Sep, 2018 |Tags: Bayer, BAY94-9027, Receives, CHMP Approval, Treatment, Haemophilia A, =12yrs, EU